CN115364179A - Traditional Chinese medicine composition for reducing blood uric acid and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for reducing blood uric acid and preparation method and application thereof Download PDFInfo
- Publication number
- CN115364179A CN115364179A CN202211043216.7A CN202211043216A CN115364179A CN 115364179 A CN115364179 A CN 115364179A CN 202211043216 A CN202211043216 A CN 202211043216A CN 115364179 A CN115364179 A CN 115364179A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- reducing blood
- blood uric
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 57
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 229940116269 uric acid Drugs 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 239000008280 blood Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 28
- 235000008113 selfheal Nutrition 0.000 claims abstract description 27
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 18
- 241000132012 Atractylodes Species 0.000 claims abstract description 17
- 201000005569 Gout Diseases 0.000 claims abstract description 16
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 241000427159 Achyranthes Species 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 235000011477 liquorice Nutrition 0.000 claims abstract description 9
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- 239000000284 extract Substances 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 26
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 13
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 10
- 229960004853 betadex Drugs 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 24
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 240000000031 Achyranthes bidentata Species 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 13
- 201000001431 Hyperuricemia Diseases 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 102100033220 Xanthine oxidase Human genes 0.000 description 6
- 229960003459 allopurinol Drugs 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 241000218202 Coptis Species 0.000 description 5
- 235000002991 Coptis groenlandica Nutrition 0.000 description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000029142 excretion Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for reducing blood uric acid and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials in parts by weight: 600-900 parts of selfheal, 10-50 parts of coptis chinensis, 10-50 parts of bighead atractylodes rhizome, 5-30 parts of coix seed, 5-30 parts of achyranthes root and 5-30 parts of liquorice. According to the invention, selfheal is used as a monarch drug, coptis chinensis, bighead atractylodes rhizome and coix seeds are used as ministerial drugs, achyranthes bidentata is used as an adjuvant drug, and liquorice is used as a conductant drug, and all the components are matched with each other, so that the blood uric acid concentration is effectively reduced, and the traditional Chinese medicine has a wide application prospect in the aspects of preventing and treating gout.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for reducing blood uric acid, and a preparation method and application thereof.
Background
Gout (gout) is a group of clinical syndromes caused by deposition of uric acid at joints and the like in vivo due to purine metabolic disorder or reduction of uric acid excretion in vivo, and continuous hyperuricemia is a necessary condition for inducing gout. Uric acid is a product of purine metabolism, has limited solubility in body fluid, causes hyperuricemia in vivo or decreases uric acid excretion when purine metabolism is disturbed or purine ingestion is excessive, and causes uric acid accumulated in body fluid to exceed its saturation concentration, and easily precipitates in tissues, causing hyperuricemia (hyperuricemia), and about 5-12% of patients with hyperuricemia finally develop gout. Hyperuricemia is the most important biochemical basis of gout and is the most dangerous factor for inducing gout, so that the control of uric acid level is the key for preventing and reducing blood uric acid, and the reduction of blood uric acid concentration through medicines is an effective method for preventing gout.
The existing uric acid lowering drugs comprise two categories of drugs for promoting uric acid excretion and drugs for inhibiting uric acid synthesis, wherein the drugs for promoting uric acid excretion are represented by benzbromarone (benzbromarone), but are often accompanied by side effects such as rash, fever, kidney damage and the like; drugs that inhibit uric acid synthesis act by acting on xanthine oxidase (xanthine oxidase), a key enzyme in the process of uric acid production, and the most clinically used xanthine oxidase inhibitor is allopurinol; allopurinol has definite curative effect, however, about 2 percent of patients are allergic to allopurinol, and about 3 to 10 percent of patients have adverse reactions in the treatment process, can induce toxic hepatitis and have adverse reactions such as gastrointestinal reaction, leukopenia and thrombocytopenia and the like. Therefore, the research on high-efficiency anti-gout drugs is urgent.
Disclosure of Invention
The invention discloses a traditional Chinese medicine composition for reducing blood uric acid and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials in parts by weight:
600-900 parts of selfheal, 10-50 parts of coptis chinensis, 10-50 parts of bighead atractylodes rhizome, 5-30 parts of coix seed, 5-30 parts of achyranthes root and 5-30 parts of liquorice.
The Chinese medicinal composition of the invention uses prunella vulgaris and has the effective component of rosmarinic acid. Modern researches show that after a human body takes purine substances, uric acid is required to be generated under the action of xanthine oxidase, and rosmarinic acid has an inhibitory effect on the xanthine oxidase so as to inhibit the generation of the uric acid. The content of rosmarinic acid in the selfheal specified by Chinese pharmacopoeia is not less than 0.2 percent, and researches show that the content of rosmarinic acid in the selfheal in different production places can reach 0.2 to 2.3 percent. The invention takes the selfheal containing rosmarinic acid as the monarch drug in the formula; rhizoma coptidis, rhizoma atractylodis macrocephalae and semen coicis are matched as the ministerial drugs of the prescription; coptis root, rhizoma Coptidis, bitter in flavor and cold in nature, is used to clear heat and to dry dampness; bighead atractylodes rhizome, rhizoma atractylodis macrocephalae, which is used for tonifying spleen and qi, eliminating dampness and promoting diuresis, is mainly used for treating spleen deficiency, anorexia and edema; the coix seeds have the effects of excreting dampness, strengthening spleen, relaxing muscles and tendons and removing arthralgia; the three medicines are combined, and can be matched with selfheal to effectively reduce the concentration of blood uric acid and relieve the pain of meridians and joints. Achyranthes root, radix Achyranthis bidentatae, as an adjuvant drug in the recipe, has the effects of activating blood and stimulating the menstrual flow, and strengthening tendons and bones. So Licorice root, radix Glycyrrhizae can coordinate the actions of the other drugs in the recipe, relieving spasm and alleviating pain. The traditional Chinese medicine composition has compatible medicines, has the effects of clearing heat and purging fire, promoting diuresis and excreting dampness, strengthening muscles and bones and benefiting joints, and can be used for treating gout with symptoms of joint swelling, hot pain, limited activity and the like caused by damp-heat accumulation.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Reflux-extracting Prunellae Spica with ethanol solution to obtain Prunellae Spica ethanol extractive solution;
(2) Recovering ethanol from the ethanol extract of the selfheal, concentrating and purifying by using macroporous resin;
(3) Spray drying the purified extract to obtain powder 1 containing rosmarinic acid;
(4) Pulverizing part of Atractylodis rhizoma and Coicis semen to obtain powder 2;
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water, filtering the decoction, concentrating the filtrate into paste, drying, and pulverizing to obtain powder 3;
(6) Mixing powder 1, powder 2 and powder 3.
The method adopts the combination of ethanol solution extraction and macroporous resin adsorption to extract and purify the traditional Chinese medicine selfheal rich in rosmarinic acid, so that the content of the rosmarinic acid in the extract can reach 10-20%, and the traditional Chinese medicine selfheal rich in rosmarinic acid is matched with medicinal materials such as coptis chinensis, coix seeds, bighead atractylodes rhizome and the like, so that the xanthine oxidase activity can be effectively inhibited, the concentration of blood uric acid is reduced, and the effect of inhibiting the occurrence and development of gout is achieved.
According to the invention, part of the bighead atractylodes rhizome and the coix seed are directly crushed into the medicine, wherein the bighead atractylodes rhizome contains volatile components such as atractylone and the like, and part of the volatile active components are reserved after the bighead atractylodes rhizome and the coix seed are crushed into the medicine; the coix seed medicinal material has stronger powder property, and the addition of auxiliary materials in the preparation can be reduced by crushing the coix seed medicinal material into the preparation.
The coptis, the achyranthes, the liquorice and other medicines are extracted and used as medicines by a water decoction method, most of the active ingredients have better solubility in water, and the full extraction of the active ingredients can be ensured.
Preferably, in the step (1), ethanol solution with mass fraction of 40-95% is used for reflux extraction for 1-3 times, each time for 0.5-2.5 hours, and the amount of ethanol solution used for reflux extraction for each time is 4-10 times of the weight of selfheal.
Preferably, in the step (2), recovering ethanol from the ethanol extract of the selfheal until no alcohol smell exists, and concentrating; passing through D101 macroporous resin, washing with water, discarding water washing solution, eluting with 20-80% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
Preferably, the amount of water and the amount of 20-80% ethanol solution are 4 column volumes.
Preferably, in the step (3), the purified extract is added with starch and beta-cyclodextrin, and spray drying is carried out, wherein the air inlet temperature of drying is 150-160 ℃, the air exhaust temperature is 80-90 ℃, the liquid inlet volume flow is 15mL/min, and the atomizing airflow pressure is 220Pa.
Preferably, the amount of starch is 10% of the mass of the purified extract and the amount of beta-cyclodextrin is 10-15% of the mass of the purified extract.
Preferably, in the step (4), the dosage of the bighead atractylodes rhizome and the coix seed is one third of the dosage of the prescription; pulverizing, and sieving with 80 mesh sieve.
Preferably, in the step (5), water is added for 2 times, 1.5 hours each time, and the amount of the added water is 6-8 times of the weight of the medicinal materials; mixing decoctions, filtering, concentrating the filtrate to obtain soft extract with relative density of 1.25-1.30 at 80 deg.C, controlling vacuum degree at 0.08MPa or less and temperature at 70-80 deg.C, drying under reduced pressure to obtain dry extract, pulverizing, and sieving with 80 mesh sieve.
The traditional Chinese medicine composition or the traditional Chinese medicine composition prepared by the method is applied to preparing medicines for reducing blood uric acid and preventing or treating gout.
In conclusion, the invention takes the selfheal as the monarch drug, the coptis root, the bighead atractylodes rhizome and the coix seed as the ministerial drugs, the achyranthes root as the adjuvant drug and the liquorice as the conductant drug, and the selfheal, the atractylodes rhizome, the coix seed and the achyranthes root are matched with each other, so that the concentration of the blood uric acid is effectively reduced, and the invention has wide application prospect in the aspects of preventing and treating gout.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
Example 1
A traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials:
750g of selfheal, 30g of coptis chinensis, 30g of bighead atractylodes rhizome, 15g of coix seed, 15g of achyranthes bidentata and 15g of liquorice.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Taking selfheal, extracting by refluxing with 70% ethanol solution for 2 times, 1 hour each time, wherein the amount of the ethanol solution extracted each time is 6 times of the weight of the selfheal; extracting, filtering, and mixing filtrates to obtain Prunellae Spica ethanol extractive solution.
(2) Recovering ethanol from the selfheal ethanol extracting solution until no ethanol smell exists, and concentrating the solution until the mass ratio of the solution is 1; passing through D101 macroporous resin, washing with 4 times column volume of water, discarding water washing solution, eluting with 4 times column volume of 50% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
(3) Adding starch and beta-cyclodextrin into the purified extract, and spray drying to obtain powder 1 containing rosmarinic acid;
the drying air inlet temperature is controlled to be 150-160 ℃, the air exhaust temperature is controlled to be 80-90 ℃, the volume flow of the inlet liquid is 15mL/min, and the pressure of the atomizing air flow is 220Pa. The amount of starch used was 10% of the mass of the purified extract and the amount of beta-cyclodextrin used was 10% of the mass of the purified extract.
(4) One third of the prescription weight of the rhizoma atractylodis macrocephalae and semen coicis is taken, crushed and sieved by a 80-mesh sieve to obtain powder 2.
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water for 1.5 hr for 2 times, wherein the water addition amount is 8 and 6 times of the weight of the medicinal materials respectively; mixing decoctions, filtering, concentrating the filtrate to relative density of 1.25-1.30 (measured at 80 deg.C), drying the obtained soft extract under reduced pressure at vacuum degree of 0.08MPa or less and temperature of 70-80 deg.C to obtain dry extract, pulverizing, and sieving with 80 mesh sieve to obtain powder 3.
(6) Mixing powder 1, powder 2 and powder 3.
The Chinese medicinal composition can be made into pill, capsule or tablet, and can be used for reducing blood uric acid and preventing and treating gout.
Example 2
A traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials:
800g of selfheal, 20g of coptis root, 40g of bighead atractylodes rhizome, 10g of coix seed, 10g of achyranthes root and 25g of liquorice.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Taking selfheal, and extracting by refluxing 75% of ethanol solution for 3 times, wherein the amount of the ethanol solution extracted each time is 4 times of the weight of the selfheal, and each time is 0.5 hour; extracting, filtering, and mixing filtrates to obtain Prunellae Spica ethanol extractive solution.
(2) Recovering ethanol from the selfheal ethanol extracting solution until no ethanol smell exists, and concentrating the solution until the mass ratio of the solution is 1; passing through D101 macroporous resin, washing with 4 times column volume of water, discarding water washing solution, eluting with 4 times column volume of 70% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
(3) Adding starch and beta-cyclodextrin into the purified extract, and spray drying to obtain powder 1 containing rosmarinic acid;
the drying air inlet temperature is controlled to be 150-160 ℃, the air exhaust temperature is controlled to be 80-90 ℃, the volume flow of the inlet liquid is 15mL/min, and the pressure of the atomizing air flow is 220Pa. The amount of starch was 10% and the amount of beta-cyclodextrin 15% of the purified extract.
(4) Taking one third of the bighead atractylodes rhizome and the coix seed according to the weight of the prescription, crushing and sieving by a 80-mesh sieve to obtain powder 2.
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water for 1.5 hr for 2 times, wherein the water addition amount is 8 and 6 times of the weight of the medicinal materials respectively; mixing decoctions, filtering, concentrating the filtrate to relative density of 1.25-1.30 (measured at 80 deg.C), drying the obtained soft extract under reduced pressure at vacuum degree of 0.08MPa or less and temperature of 70-80 deg.C to obtain dry extract, pulverizing, and sieving with 80 mesh sieve to obtain powder 3.
(6) Mixing powder 1, powder 2, and powder 3.
The Chinese medicinal composition can be made into pill, capsule or tablet, and can be used for reducing blood uric acid and preventing and treating gout.
Example 3
A traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials:
700g of selfheal, 40g of coptis root, 20g of bighead atractylodes rhizome, 20g of coix seed, 20g of achyranthes root and 20g of liquorice.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Reflux-extracting Prunellae Spica with 80% ethanol solution for 2 times (2 hr each time), wherein the ethanol solution is 8 times of Prunellae Spica weight; extracting, filtering, and mixing filtrates to obtain Prunellae Spica ethanol extract.
(2) Recovering ethanol from the selfheal ethanol extracting solution until no ethanol smell exists, and concentrating until the mass ratio of the liquid medicine to the liquid medicine is 1; passing through D101 macroporous resin, washing with 4 times column volume of water, discarding water washing solution, eluting with 4 times column volume mass fraction 60% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
(3) Adding starch and beta-cyclodextrin into the purified extract, and spray drying to obtain powder 1 containing rosmarinic acid;
the air inlet temperature for drying is controlled to be 150-160 ℃, the air outlet temperature is controlled to be 80-90 ℃, the volume flow of inlet liquid is 15mL/min, and the pressure of atomizing airflow is 220Pa. The amount of starch was 10% of the purified extract mass and the amount of beta cyclodextrin was 10% of the purified extract mass.
(4) One third of the prescription weight of the rhizoma atractylodis macrocephalae and semen coicis is taken, crushed and sieved by a 80-mesh sieve to obtain powder 2.
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water for 1.5 hr for 2 times, wherein the water amount is 8 and 6 times of the medicinal materials respectively; mixing decoctions, filtering, concentrating the filtrate to relative density of 1.25-1.30 (measured at 80 deg.C), drying the obtained soft extract under reduced pressure at vacuum degree of 0.08MPa or less and temperature of 70-80 deg.C to obtain dry extract, pulverizing, and sieving with 80 mesh sieve to obtain powder 3.
(6) Mixing powder 1, powder 2, and powder 3.
The Chinese medicinal composition can be made into pill, capsule or tablet, and can be used for reducing blood uric acid and preventing and treating gout.
Example 4
Experimental animals: kunming breed mice, SPF grade, male, supplied by Liaoning Biotechnology, inc., laboratory animal production license number: SCXK 2020-0001 (Liao) is provided.
License number for experimental animals: SYXK (Ji) 2022-0004. The feeding environment is a shielded environment, and food and water can be freely taken; the feed is provided by the Beijing department Australian cooperative feed Co., ltd, and the production license number is as follows: SCXK 2020-0004, batch number: 22013211.
the weight of a male Kunming mouse is 20-22 g, the male Kunming mouse is randomly divided into 7 groups, which are respectively a normal control group, a model control group, allopurinol (provided by combined Feitel pharmacy Co., ltd., batch number: 20180502) 5mg/kg group, simiao pills (rhizoma atractylodis, radix achyranthis bidentatae, golden cypress and semen coicis) 4g/kg group, an example 1 traditional Chinese medicine composition 2g/kg group and an example 1 traditional Chinese medicine composition 1g/kg group, and each group is 10 mice.
Performing intragastric administration on each group of 8 (am) and 00 (am) every day, preparing a liquid medicine by using 0.25% sodium carboxymethylcellulose (CMC) aqueous solution for each administration group, and performing intragastric administration, wherein the intragastric administration volume is 20mL/kg, and the continuous administration lasts for 6 days; gavage of the normal control group and the model control group was performed with an equivalent amount of 0.25% CMC solution.
After 1 hour of daily administration, 250mg/kg of oteracil potassium (supplied by Dalian biotechnology, inc., lot A0925A, prepared to a desired concentration with distilled water immediately before use, adjusted to pH7.5 with 1NKOH solution) was intraperitoneally administered to each of the model control group and each administration group, and the normal control group was intraperitoneally injected with an equal amount of physiological saline. Blood is taken from the retrobulbar venous plexus of the mouse 1h after the final potassium oxonate administration, the centrifugation is carried out for 10min at 3000rpm/min, serum is taken, and the serum uric acid level is determined by adopting a phosphotungstic acid reduction method according to the specification of a uric acid determination kit (provided by Nanjing institute of bioengineering, batch No. 20212225).
Statistical analysis data were in ± s, and a one-way anova was used for group comparisons.
The results are shown in Table 1. The blood uric acid level of the model control group animals is compared with that of the normal control group, and the difference has statistical significance (P < 0.01), which indicates that the model is successful. The positive drug allopurinol 5mg/kg has very obvious inhibition effect (P < 0.001) on the influence of the serum uric acid level of a hyperuricemia mouse model, the Simiao pill 4g/kg group has obvious inhibition effect (P < 0.05) on the influence of the serum uric acid level of the hyperuricemia mouse model, and the composition 4g/kg group and the composition 2g/kg group in the example 1 have obvious inhibition effect (P < 0.01) on the influence of the serum uric acid level of the hyperuricemia mouse model. 1g/kg has obvious inhibiting effect on the influence of the serum uric acid level of a hyperuricemia mouse model (P is less than 0.05).
TABLE 1
Comparing with a normal control group: : # p <0.001, compared to the model control group: * p <0.05, p <0.01, p <0.001.
The research adopts a potassium oxonate induced mouse hyperuricemia model, takes allopurinol as a positive control, and researches the influence of intragastric administration of the traditional Chinese medicine composition of different administration concentrations on the serum uric acid level of the hyperuricemia mouse model. The results show that the traditional Chinese medicine composition of the embodiment 1 has a certain effect of reducing the blood uric acid at 4g/kg and 2g/kg, the effect is obviously better than that of the Simiao pill group, and the inhibition of xanthine oxidase is one of the action targets.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to the above-described embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. A traditional Chinese medicine composition for reducing blood uric acid is characterized by comprising the following raw materials in parts by weight:
600-900 parts of selfheal, 10-50 parts of coptis chinensis, 10-50 parts of bighead atractylodes rhizome, 5-30 parts of coix seed, 5-30 parts of achyranthes root and 5-30 parts of liquorice.
2. The preparation method of the traditional Chinese medicine composition for reducing blood uric acid, according to claim 1, is characterized by comprising the following steps:
(1) Reflux-extracting Prunellae Spica with ethanol solution to obtain Prunellae Spica ethanol extractive solution;
(2) Recovering ethanol from Prunellae Spica ethanol extractive solution, concentrating, and purifying with macroporous resin;
(3) Spray drying the purified extract to obtain powder 1 containing rosmarinic acid;
(4) Pulverizing part of Atractylodis rhizoma and Coicis semen to obtain powder 2;
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water, filtering the decoction, concentrating the filtrate into paste, drying, and pulverizing to obtain powder 3;
(6) Mixing powder 1, powder 2 and powder 3.
3. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 2, wherein,
in the step (1), ethanol solution with the mass fraction of 40-95% is used for reflux extraction for 1-3 times, each time lasts for 0.5-2.5 hours, and the amount of the ethanol solution for reflux extraction for each time is 4-10 times of the weight of the selfheal.
4. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 2, wherein,
in the step (2), recovering ethanol from the ethanol extract of the selfheal until no alcohol smell exists, and concentrating; passing through D101 macroporous resin, washing with water, discarding water washing solution, eluting with 20-80% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
5. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 4, wherein,
the dosage of the water and the ethanol solution with the mass fraction of 20-80 percent are 4 times of the column volume.
6. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 2, wherein,
in the step (3), starch and beta cyclodextrin are added into the purified extract, spray drying is carried out, the air inlet temperature for drying is 150-160 ℃, the air exhaust temperature is 80-90 ℃, the liquid inlet volume flow is 15mL/min, and the atomizing airflow pressure is 220Pa.
7. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 6, wherein,
the amount of starch is 10% of the purified extract mass and the amount of beta-cyclodextrin is 10-15% of the purified extract mass.
8. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 2, wherein,
in the step (4), the dosage of the largehead atractylodes rhizome and the coix seed is one third of the dosage of the prescription; pulverizing, and sieving with 80 mesh sieve.
9. The preparation method of a Chinese medicinal composition for reducing blood uric acid as claimed in claim 2, wherein,
in the step (5), water is added for 2 times, 1.5 hours each time, and the amount of the added water is 6-8 times of the weight of the medicinal materials; mixing decoctions, filtering, concentrating the filtrate to obtain soft extract with relative density of 1.25-1.30 at 80 deg.C, controlling vacuum degree at 0.08MPa or less and temperature at 70-80 deg.C, drying under reduced pressure to obtain dry extract, pulverizing, and sieving with 80 mesh sieve.
10. Use of the Chinese medicinal composition of claim 1 or the Chinese medicinal composition prepared by the method of any one of claims 2 to 9 in the preparation of a medicament for reducing blood uric acid and preventing or treating gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211043216.7A CN115364179B (en) | 2022-08-29 | 2022-08-29 | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211043216.7A CN115364179B (en) | 2022-08-29 | 2022-08-29 | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115364179A true CN115364179A (en) | 2022-11-22 |
| CN115364179B CN115364179B (en) | 2024-02-06 |
Family
ID=84068792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211043216.7A Active CN115364179B (en) | 2022-08-29 | 2022-08-29 | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115364179B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596295A (en) * | 2009-07-03 | 2009-12-09 | 云南天秀植物科技开发有限公司 | A kind of pharmaceutical composition and preparation technology thereof who is used for the treatment of gout |
| CN102018759A (en) * | 2009-09-17 | 2011-04-20 | 上海中医药大学附属曙光医院 | Rosmarinic acid, rosmarinic acid-containing common selfheal fruit-spike active ingredient and preparation methods and application thereof to prevention and treatment of cancer postoperative metastasis |
| CN102671076A (en) * | 2012-05-14 | 2012-09-19 | 吴敏 | Medicament for treating gout |
| CN104997843A (en) * | 2015-08-07 | 2015-10-28 | 国药集团健康产业研究院有限公司 | Application of selfheal extract for making blood uric acid decreasing medicine or food |
| CN105055510A (en) * | 2015-09-14 | 2015-11-18 | 青岛大学 | Effective part of perilla leaf resisting hyperuricemia and preparation method and application thereof |
-
2022
- 2022-08-29 CN CN202211043216.7A patent/CN115364179B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596295A (en) * | 2009-07-03 | 2009-12-09 | 云南天秀植物科技开发有限公司 | A kind of pharmaceutical composition and preparation technology thereof who is used for the treatment of gout |
| CN102018759A (en) * | 2009-09-17 | 2011-04-20 | 上海中医药大学附属曙光医院 | Rosmarinic acid, rosmarinic acid-containing common selfheal fruit-spike active ingredient and preparation methods and application thereof to prevention and treatment of cancer postoperative metastasis |
| CN102671076A (en) * | 2012-05-14 | 2012-09-19 | 吴敏 | Medicament for treating gout |
| CN104997843A (en) * | 2015-08-07 | 2015-10-28 | 国药集团健康产业研究院有限公司 | Application of selfheal extract for making blood uric acid decreasing medicine or food |
| CN105055510A (en) * | 2015-09-14 | 2015-11-18 | 青岛大学 | Effective part of perilla leaf resisting hyperuricemia and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 苗艳波 等: "加味四妙胶囊抗痛风性关节炎实验研究", 北华大学学报(自然科学版), vol. 18, no. 05, pages 606 - 608 * |
| 陈桂德: "自拟排石汤加减治疗原发性痛风50例", 广西中医药, no. 04, pages 19 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115364179B (en) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108477612B (en) | Dendrobium nutrition powder containing dendrobium officinale purified extract and preparation method thereof | |
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| KR101088539B1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN105727144A (en) | Traditional Chinese medicine composition for treating bronchitis and preparation method thereof | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN1919272B (en) | Traditional Chinese medicine concentrated pill | |
| CN113679794A (en) | Uric acid-reducing sunflower disc composition and preparation method thereof | |
| CN103083433A (en) | Drug for treating rheumatism and rheumatoid sciatica | |
| CN1290544C (en) | Medicine for treating acute and chronic hepatitis | |
| CN114377095A (en) | Fructus amomi-sandalwood volatile oil extraction method, capsule for treating gastritis and preparation method of capsule | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
| CN112826917A (en) | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1969973A (en) | Chinese medicinal soft capsule for treating stomachache | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN101194959B (en) | Capsule for treating headache and method for preparing the same | |
| CN104840706A (en) | Physiologically multifunctional traditional Chinese medicine compound preparation and preparing method thereof | |
| CN1319546C (en) | Delayed-releasing preparation for treating osteoporosis | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN112168931B (en) | A pharmaceutical composition for treating oral ulcer, and its preparation method | |
| CN114404433B (en) | Pinoresinol diglucoside composition for improving microcirculation and preparation method thereof | |
| CN101757460A (en) | Traditional Chinese medicine preparation for treating gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |